• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Selecting seals for new insulin delivery devices

January 13, 2017 By Danielle Kirsh

insulin drug delivery

High technical precision in insulin pump seals is important for ensuring that seals meet regulatory requirements and will be operationally sound.

Drew Rogers, global director of healthcare & medical, Trelleborg Sealing Solutions

With more than 400 million adults worldwide suffering from diabetes and 1.5 million deaths directly attributed to the disease each year, it’s no wonder so many scientists, inventors and pharmaceutical companies are turning their attention to improving insulin delivery devices.

Diabetes is not only one of the most common chronic diseases; it is also complex and difficult to treat. Insulin is often administered between meals to keep blood sugar within a target range and at mealtimes based on the number of carbohydrates to be ingested. Basal insulin, also known as background insulin, is made by the pancreas and is the constantly present insulin in the body. While Bolus insulin is that extra insulin that the pancreas delivers in response to glucose ingested through meals. Insulin delivery devices aim to treat diabetes through adequate basal-bolus therapy.

A variety of insulin types are used to regulate blood-sugar levels, including fast-acting, short-acting, intermediate-acting, long-acting and pre-mixed. These are introduced into the body via a wide variety of devices, including traditional syringes, injection ports, insulin pens, conventional insulin pumps and patch pumps.

Get the full story on our sister site, Medical Design & Outsourcing.

Filed Under: Diabetes Tagged With: Trelleborg Sealing Solutions

IN CASE YOU MISSED IT

  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development
  • Ypsomed brings autoinjector for dual GCG/GLP-1 delivery to China

About Danielle Kirsh

Danielle Kirsh is an award-winning journalist and senior editor for Medical Design & Outsourcing, MassDevice, and Medical Tubing + Extrusion, and the founder of Women in Medtech and lead editor for Big 100. She received her bachelor's degree in broadcast journalism and mass communication from Norfolk State University and is pursuing her master's in global strategic communications at the University of Florida. You can connect with her on Twitter and LinkedIn, or email her at dkirsh@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS